Last reviewed · How we verify
Sublingual film containing Dexmedetomidine
Sublingual film containing Dexmedetomidine is a Small molecule drug developed by BioXcel Therapeutics Inc. It is currently in Phase 1 development. Also known as: BXCL501.
At a glance
| Generic name | Sublingual film containing Dexmedetomidine |
|---|---|
| Also known as | BXCL501 |
| Sponsor | BioXcel Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department (PHASE4)
- Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder (PHASE4)
- Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) (PHASE3)
- Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) (PHASE3)
- Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder (PHASE2)
- Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder (PHASE1)
- Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) (PHASE3)
- Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sublingual film containing Dexmedetomidine CI brief — competitive landscape report
- Sublingual film containing Dexmedetomidine updates RSS · CI watch RSS
- BioXcel Therapeutics Inc portfolio CI
Frequently asked questions about Sublingual film containing Dexmedetomidine
What is Sublingual film containing Dexmedetomidine?
Sublingual film containing Dexmedetomidine is a Small molecule drug developed by BioXcel Therapeutics Inc.
Who makes Sublingual film containing Dexmedetomidine?
Sublingual film containing Dexmedetomidine is developed by BioXcel Therapeutics Inc (see full BioXcel Therapeutics Inc pipeline at /company/bioxcel-therapeutics-inc).
Is Sublingual film containing Dexmedetomidine also known as anything else?
Sublingual film containing Dexmedetomidine is also known as BXCL501.
What development phase is Sublingual film containing Dexmedetomidine in?
Sublingual film containing Dexmedetomidine is in Phase 1.
Related
- Manufacturer: BioXcel Therapeutics Inc — full pipeline
- Also known as: BXCL501